Fluoxetine

is prescribed to treat:

• Depression, ocd, bulimia, and panic disorder • Various related conditions in the mental health category • Associated symptoms and complications

It is an important medication that helps manage these conditions effectively.

Fluoxetine (Prozac) is a selective serotonin reuptake inhibitor used for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It was the first SSRI to reach wide use and it remains distinctive within the class for one reason above all: an exceptionally long half-life that changes how it is started, stopped, and combined.

Mechanism of Action

Fluoxetine blocks the presynaptic serotonin transporter, reducing reuptake and increasing synaptic serotonin availability. As with every SSRI, transporter blockade is immediate while clinical benefit takes two to six weeks, implying that the therapeutic effect comes from downstream adaptation — receptor desensitisation, altered gene expression, changes in neuroplasticity — rather than from the raised serotonin itself.

What sets fluoxetine apart is pharmacokinetic. Its own half-life is one to four days, and its active metabolite norfluoxetine has a half-life of seven to fifteen days. Steady state therefore takes weeks to reach, and after stopping, meaningful drug levels persist for a month or more.

That property has three consequences. Fluoxetine causes far less discontinuation syndrome than short-half-life SSRIs, because it self-tapers — a genuine advantage for patients likely to miss doses or stop abruptly. It can be dosed weekly in maintenance. But it also means a five-week washout is required before starting an MAO inhibitor, and that any interaction it causes persists long after the drug is stopped.

Fluoxetine is also a potent CYP2D6 inhibitor, which is its most consequential difference from escitalopram and sertraline. It raises levels of CYP2D6 substrates including metoprolol and certain antiarrhythmics, and it reduces conversion of tamoxifen to its active metabolite — a clinically important interaction in breast cancer patients, where an alternative antidepressant is preferred.

Clinical Use

Fluoxetine is a reasonable first-line antidepressant and has the strongest evidence base in the class for adolescent depression, where it is the usual first choice. It is effective in OCD, though that indication typically requires higher doses and a longer trial — often 8 to 12 weeks — than depression does, and declaring failure at six weeks in OCD is a common error.

Its activating profile distinguishes it clinically. Fluoxetine is more likely than other SSRIs to cause initial jitteriness, anxiety, and insomnia, which suits a patient with prominent fatigue and hypersomnia and suits poorly a patient whose depression is dominated by anxiety and agitation. Morning dosing helps with the insomnia.

An adequate trial means an adequate dose maintained for at least four to six weeks — the most frequent error in antidepressant management is concluding failure earlier or at a subtherapeutic dose. Sexual dysfunction is the most common persistent side effect and the most common unspoken reason for stopping; asking directly rather than waiting allows for dose reduction, a switch, or augmentation. The St. Pete mental health guide covers local options, and our psychiatric team pairs medication with therapy referral.

Monitoring and Follow-Up

Follow up within one to two weeks of starting, particularly in younger patients given the activating profile and the boxed warning, then at four to six weeks to assess response. Standardised measures such as the PHQ-9 make partial response visible, which is the situation most often requiring a decision.

No routine laboratory monitoring is required, but sodium warrants attention in older adults, since SSRIs cause hyponatremia through SIADH — typically in the first weeks, presenting as confusion, unsteadiness, or falls rather than as anything obviously chemical.

The long half-life shapes follow-up in a way clinicians sometimes forget. Dose changes take weeks to express fully, so assessing a titration after one week underestimates it. Conversely, a patient who stops fluoxetine and feels fine for three weeks before deteriorating is experiencing delayed relapse rather than a demonstration that they never needed it. The SSRI discontinuation article covers the general problem, though fluoxetine is the class exception. The National Institute of Mental Health provides patient-level background on treatment expectations.

After response, continue for at least six to twelve months following remission of a first episode and longer with recurrent illness. The MedlinePlus fluoxetine entry carries the prescribing detail.

Weekly dosing is a genuine option that few other antidepressants allow. Once a patient is stable, a weekly formulation maintains adequate levels because of the long half-life, and for someone who finds daily pill-taking difficult, or who wants a lower-effort maintenance phase, it is worth knowing about. It is not appropriate during initiation or dose-finding, and it is a poorer choice where precise dose control matters, but as a maintenance strategy in a stable patient it removes a real adherence barrier that is otherwise addressed only by reminders and pill organisers.

Special Populations

Antidepressants carry a boxed warning about increased suicidal thinking in patients under 25 during early treatment. This calls for closer follow-up rather than avoidance — fluoxetine remains the best-evidenced option in adolescent depression, and untreated depression carries substantial risk.

In pregnancy, SSRIs are used when the illness warrants it; sertraline has the largest dataset, and fluoxetine's long half-life means neonatal exposure persists longer, which is a consideration near delivery. In older adults, hyponatremia, falls, bleeding risk, and the extensive interaction profile all warrant caution, and a shorter-acting, less interacting SSRI is often preferred. Hepatic impairment slows clearance further. Fluoxetine is contraindicated within two weeks after an MAO inhibitor and requires five weeks before starting one.

When to Contact Your Doctor

Seek urgent care for agitation with fever, rapid heart rate, muscle rigidity or twitching, sweating, and confusion, which together suggest serotonin syndrome — a risk raised by triptans, tramadol, linezolid, and St. John's wort. Contact your clinician promptly for new or worsening thoughts of self-harm, marked agitation or restlessness, or a switch into unusually elevated mood or reduced need for sleep, which may indicate an underlying bipolar diathesis. Report confusion, marked unsteadiness, or falls. Unusual bruising or bleeding warrants a medication review. Tell any prescriber you take fluoxetine even after stopping it, because the interaction potential persists for weeks.

To review whether your dose is adequate, discuss side effects, or plan a change, contact us or schedule a visit.